Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time. This type of delivery can enhance efficacy and patient compliance as compared to immediate release formats for the same drug. Hypermatrix technology is the company’s propriety product and allows for the intelligent and efficient design of drugs through the precise control of several key variables including varying drug attributes and patient requirements. For more information, visit the company’s website at www.intellipharmaceutics.com